<SEC-DOCUMENT>0001144204-15-059483.txt : 20151015
<SEC-HEADER>0001144204-15-059483.hdr.sgml : 20151015
<ACCEPTANCE-DATETIME>20151014203336
ACCESSION NUMBER:		0001144204-15-059483
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20151015
DATE AS OF CHANGE:		20151014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-204050
		FILM NUMBER:		151159035

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v422204_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Filed Pursuant to Rule 424(b)(3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-204050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Champions Oncology, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2,939,252 shares of Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1,616,594 shares of Common Stock issuable
upon the exercise of Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the resale by certain selling security holders of Champions Oncology, Inc. of up to 4,555,846 shares of our common stock in
connection with the resale of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">up to 2,939,252 shares of common stock issued to certain of the selling security holders in the
registrant&rsquo;s private placement offering that occurred on March 13, 2015; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">up to 1,616,594 shares of common stock issuable upon the exercise of warrants issued to certain
selling security holders in the offering that occurred on March 13, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling security holders
may offer to sell the shares of common stock being offered in this prospectus at fixed prices, at prevailing market prices at the
time of sale, at varying prices, or at negotiated prices. We do not know when or in what amount the selling security holders may
offer the securities for sale. The selling security holders may sell any, all or none of the securities offered by this prospectus.
We provide more information about how the selling security holders may sell or otherwise dispose of their shares of common stock
in the section entitled &ldquo;Plan of Distribution.&rdquo; The selling security holders will pay all brokerage fees and commissions
and similar expenses. We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to the registration
of the shares with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive proceeds
from the sale of shares by the selling security holders. Any proceeds received by us from the exercise of warrants by the selling
security holders will be used for general corporate purposes. The selling security holders and any brokers executing sell orders
on behalf of the selling security holders may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;). Commissions received by a broker executing sell orders may be deemed to
be underwriting commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incorporated
by reference into this prospectus the information contained in the registrant's Annual Report on Form 10-K for the fiscal year
ended April 30, 2015, filed on July 29, 2015 (the &ldquo;Form 10-K&rdquo;), the Company&rsquo;s Quarterly Report on Form 10-Q for
the three months ended July 31, 2015, filed on September 11, 2015, the registrant&rsquo;s Definitive Proxy Statement filed on August
28, 2015 and amended on September 1, 2015 and in its Current Report on Form 8-K filed on July 23, 2015, August 13, 2015, August
21, 2015, and August 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
presently quoted on the Nasdaq Capital Market under the symbol &ldquo;CSBR.&rdquo; On October 13, 2015, the last reported sale
price for our common stock on the Nasdaq Capital Market was $5.35 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our
securities involve significant risks. See &ldquo;Risk Factors&rdquo; beginning on page 10 to read about factors you should consider
before buying shares of the common stock.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">This prospectus
is dated October 14, 2015</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>TABLE OF CONTENTS </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_004">PRICE RANGE OF COMMON STOCK</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">SELLING SECURITY HOLDERS</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">DESCRIPTION OF SECURITIES</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CHAMPIONS ONCOLOGY, INC. HAS NOT REGISTERED
THE SHARES OF COMMON STOCK THAT MAY BE SOLD BY THE SELLING SECURITY HOLDERS UNDER THE SECURITIES LAWS OF ANY STATE. SELLING SECURITY
HOLDERS, AND ANY BROKERS OR DEALERS, EFFECTING TRANSACTIONS IN THE SHARES SHOULD CONFIRM THAT THE SHARES HAVE BEEN REGISTERED UNDER
THE SECURITIES LAWS OF THE STATE OR STATES IN WHICH SALES OF THE SHARES OCCUR AS OF THE TIME OF SUCH SALES, OR THAT THERE IS AN
AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES LAWS OF SUCH STATES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS PROSPECTUS IS NOT AN OFFER TO SELL
ANY SECURITIES OTHER THAN THE SHARES OF COMMON STOCK FOR SALE BY THE SELLING SECURITY HOLDERS. THIS PROSPECTUS IS NOT AN OFFER
TO SELL SECURITIES IN ANY CIRCUMSTANCES IN WHICH SUCH AN OFFER IS UNLAWFUL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered
or made available to you. We have not, and the selling security holders have not, authorized anyone to provide you with any information
other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available
to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others
may give you. This prospectus may only be used where it is legal to offer and sell shares of our common stock. The information
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or
any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed
since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not making an
offer of these securities in any jurisdiction where the offer is not permitted. For investors outside the United States: We have
not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and
the distribution of this prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains
forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency,
goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are
based on our current expectations and projections about future events and they are subject to risks and uncertainties known and
unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, you
can identify forward-looking statements by terminology, such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo; &ldquo;should&rdquo;,
&ldquo;could&rdquo; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates,
assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking
statements are qualified in their entirety by reference to the factors discussed throughout this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this
prospectus and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of
which this prospectus is part, completely and with the understanding that our actual future results may be materially different
from what we expect. You should assume that the information appearing in this prospectus is accurate as of the date on the front
cover of this prospectus only. Because the risk factors referred to above could cause actual results or outcomes to differ materially
from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any
forward-looking statements. These risks and uncertainties, along with others, are described above under the heading &ldquo;Risk
Factors.&rdquo; Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict
which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
We qualify all of the information presented in this prospectus, and particularly our forward-looking statements, by these cautionary
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus also includes estimates
of market size and industry data that we obtained from industry publications and surveys and internal company sources. The industry
publications and surveys used by management to determine market size and industry data contained in this prospectus have been obtained
from sources believed to be reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
the information contained elsewhere in or incorporated by reference into this prospectus. This summary does not contain all of
the information that you should consider before deciding whether to exercise your subscription rights. You should carefully read
this entire prospectus, including the information under the heading &ldquo;Risk Factors,&rdquo; and the documents incorporated
by reference into this prospectus, which are described under the heading &ldquo;Incorporation of Certain Information by Reference.&rdquo;
In this prospectus, all references to the &ldquo;Company,&rdquo; &ldquo;Champions Oncology&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; refer to Champions Oncology, Inc., a Delaware corporation, unless the context otherwise requires or where
otherwise indicated. All share amounts and stock prices relating to our common stock contained in this prospectus give effect to
a 1-for-12 reverse split of our shares of common stock, which was effected on August 11, 2015.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">Champions Oncology,
Inc. is engaged in the development and sale of advanced technology solutions and products to personalize the development and use
of oncology drugs.&nbsp;&nbsp;The Company&rsquo;s TumorGraft Technology Platform is a novel approach to personalizing cancer care,
based upon the implantation of human tumors in immune-deficient mice.&nbsp;&nbsp;The Company uses this technology, in conjunction
with related services, to offer solutions for two customer groups:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Personalized Oncology Solutions, or &ldquo;POS&rdquo;, business, which provides services to
physicians and patients looking for information to help guide the development of personalized treatment plans.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Translational Oncology Solutions, or &ldquo;TOS&rdquo;,
business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development
that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TumorGraft Technology Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">Our technology platform
consists of processes, physical tumors, and information that we use to personalize the development and use of oncology drugs.&nbsp;&nbsp;Our
process technology, which we call &ldquo;TumorGrafts,&rdquo; involves the:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">implantation of human tumor fragments in immune-deficient mice;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expansion of the original human tumor into a larger colony of mice through the passage of the tumor
to a limited number of generations of mice;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">treatment of the implanted mice with oncology drugs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine
the response of the tumor to the drug.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">Our process is used
for our POS business to test numerous drugs or drug combinations against a single patient&rsquo;s tumor in the mice to determine
which therapy results in the most efficacious response from the tumor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">Our technology platform
also includes a bank of&nbsp;tumors that we have acquired, collected, processed, validated, and stored for use in our TOS business,
which we call our &ldquo;TumorBank.&rdquo;&nbsp;&nbsp;We implant these tumors in mice to provide pharmaceutical and biotechnology
companies the opportunity to test oncology compounds on multiple tumors to test efficacy and simulate the results of human clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">We are also developing
an extensive database of information about the tumors in our TumorBank.&nbsp;&nbsp;We expect that this database will include certain
information about the patient (e.g. age, gender), the response of the tumors to different oncology drugs or drug combinations,
mutational status of key oncogenes, and other genetic and epigenetic data about each tumor.&nbsp;&nbsp;Our intention is to use
this database to provide our pharmaceutical and biotechnology customers with information that may assist them with their drug development
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy is to
use TumorGrafts as a platform technology to drive multiple synergistic revenue streams. We continue to build this platform with
investments in research and development. Our goal is to populate our TumorBank and its related database with tumors and information
we receive from our POS business, research collaborations and validation studies. The tumors and information in the TumorBank are
then available for TOS studies. We believe that the result is well-differentiated products for patients, physicians, and drug development
companies. In addition, we are looking for additional opportunities to utilize the data we are gathering about the tumors to develop
proprietary biomarkers and signatures of response that can predict the resistance or sensitivity of individual patients to oncology
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Personalized Oncology Solutions Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our POS business offers
physicians and patients information to help guide the development of personalized treatment plans.&nbsp;&nbsp;Our core products,
TumorGraft implants and drug panels, previously known as studies, utilize TumorGraft technology to empirically test the response
of a patient&rsquo;s tumor to multiple oncology drugs or drug combinations.&nbsp;&nbsp;The response of the tumors in the mice is
tracked over time and analyzed to determine which drug or drug combination is providing the highest level of tumor growth inhibition
in the mice.&nbsp;&nbsp;Our data, which is currently limited in nature, indicates that there may be a correlation between the response
to drugs of a tumor in a mouse with the response to drugs of a tumor in a patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our
core TumorGraft POS products, we&nbsp;offer non-core related POS products to our customers, including personalized tumor boards,
previously known as tumor panels, and gene sequencing.&nbsp;&nbsp;Personalized tumor boards are designed to provide access to oncologists
with expertise in particular tumor types.&nbsp;&nbsp; We also provide access to gene sequencing that analyzes the genetic makeup
of patient&rsquo;s tumor for the purpose of identifying potentially useful drugs. We will continue to offer related personal oncology
products to our customers; however, we expect future POS revenues to be driven by our core products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on the internet,
word of mouth, and a small sales force to market these services to patients and physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Translational Oncology Solutions Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our TOS business utilizes
our technology platform to assist pharmaceutical and biotechnology companies with their drug development process.&nbsp;&nbsp;We
provide studies, or license tumors for use in studies, that we believe may predict the efficacy of experimental oncology drugs
or approved drugs as stand-alone therapies or in combination with other drugs and can stimulate the results of human clinical trials.&nbsp;&nbsp;These
studies include in vivo studies that rely on implanting multiple tumors from our TumorBank in mice and testing the therapy of interest
on these tumors.&nbsp;&nbsp;Studies may also include bioinformatics analyses that reveal the differences in the genetic signatures
of the tumors that responded to a therapy as compared to the tumors that did not respond.&nbsp;&nbsp;Our studies can be used to
determine which types of cancer, if any, may be inhibited by a drug.&nbsp;&nbsp;The studies can also be used to identify specific
sub-populations, often characterized by particular genetic mutations that are differentially sensitive or resistant to a drug or
drug combination.&nbsp;&nbsp;These studies, used in pre-clinical testing or during phase I or II of a clinical trial, can help
guide the clinical development path of new compounds or find new indications or combinations for compounds that are already approved
by the United States Food and Drug Administration, or FDA. We believe that the results may lead to lower costs and shorter timeframes
for drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sales and marketing
efforts are dependent on a dedicated sales force that sells directly to pharmaceutical and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Associated with Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject
to numerous risks and uncertainties, including those highlighted in the section titled &ldquo;Risk Factors&rdquo; immediately following
this prospectus summary. These risks include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">We historically incurred losses from operating activities, expect losses for the foreseeable future,
require significant capital and may never achieve profitability.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">We may not be able to maintain or increase our revenues due to our reduction in POS service prices,
the length of time it takes to conduct TumorGrafts, the uncertainty of whether TumorGrafts will successfully implant and the limited
information about the correlation between the response to drugs of a tumor in mice with the response to those drugs of the tumor
in patients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Our business could be adversely impacted by changes in the FDA's regulations.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Our laboratory is subject to regulation and licensure requirements, and the healthcare industry is
highly regulated; we may face substantial penalties, and our business activities may be impacted, if we fail to comply.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">If our laboratory facility is damaged or destroyed, we have a dispute with our landlord, or our mice
population has a health crisis, our business would be negatively affected.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">We have limited experience marketing and selling our products&nbsp;and may need to rely on third parties
to successfully market and sell our products and generate revenues.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">We will continue to be dependent upon key employees.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Because our industry is very competitive and many of our competitors have substantially greater capital
resources and more experience in research and development, we may not succeed in selling or increasing sales of our products and
technologies.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">If we are unable to protect our intellectual property, we may not be able to compete as effectively.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Claims by others that our products infringe their patents or other intellectual property rights could
adversely affect our financial condition.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Insiders own a significant amount of the outstanding common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2015,
the Registrant filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware that effected a 1-for-12 reverse stock split of the Company&rsquo;s common stock, a copy and description
of which is included in the Registrant&rsquo;s Form 8-K filed with the Commission on August 13, 2015, and is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 21, 2015,&nbsp;the
Company&rsquo;s common stock was approved for listing on the Nasdaq Capital Market under the trading symbol &ldquo;CSBR.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following selected
financial data as of and for the years ended April 30, 2015 and 2014 is presented after giving effect to the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">At April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Common Stock, $0.001 par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Shares Authorized</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">200,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">125,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shares Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,963,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,843,508</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9.25pt">Shares Outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,702,237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,573,822</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended April 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 74%; padding-bottom: 1pt">Net Loss per common share outstanding, basic and diluted</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%; border-bottom: Black 1pt solid">$</TD>
    <TD STYLE="text-align: right; width: 10%; border-bottom: Black 1pt solid">(2.16</TD>
    <TD STYLE="text-align: left; width: 1%; padding-bottom: 1pt">)</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%; border-bottom: Black 1pt solid">$</TD>
    <TD STYLE="text-align: right; width: 10%; border-bottom: Black 1pt solid">(1.33</TD>
    <TD STYLE="text-align: left; width: 1%; padding-bottom: 1pt">)</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.75pt; padding-left: 9pt; padding-bottom: 2.5pt">Weighted Average Common Shares outstanding basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5,985,346</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5,573,812</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>July 31,</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Common Stock, $0.001 par value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Shares Authorized</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">200,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">125,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shares Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,963,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,843,508</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 9.25pt">Shares Outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,702,237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,573,822</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>July 31,</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 74%">Net Loss per common share outstanding, basic and diluted</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 10%">(0.33</TD>
    <TD STYLE="text-align: left; width: 1%">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 10%">(0.64</TD>
    <TD STYLE="text-align: left; width: 1%">)</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.75pt; padding-left: 9pt; padding-bottom: 2.5pt">Weighted Average Common Shares outstanding basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">8,702,237</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5,573,812</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our internet website
address is <U>www.championsoncology.com</U>.&nbsp;&nbsp;Information on our website is not part of this prospectus. Through our
website, we make available, free of charge, access to all reports filed with the United States Securities and Exchange Commission,
or SEC, including our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, our Proxy
Statements on Schedules 14A and amendments to those reports, as filed with or furnished to the SEC pursuant to Section 13(a) or
15(d) of the Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with,
or furnish it to, the SEC.&nbsp;&nbsp;Copies of any materials we file with, or furnish to, the SEC can also be obtained free of
charge through the SEC&rsquo;s website at http://www.sec.gov or at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E.,
Room 1580, Washington, DC 20549.&nbsp;&nbsp;You may obtain information on the operation of the Public Reference Room by calling
the SEC at 1-800-SEC-0330.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
are located at One University Plaza, Suite 307, Hackensack, NJ 07601. Our telephone number is (201) 808-8400.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>The Offering</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 49%; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Common stock that may be offered by the selling security holders:</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 2,939,252</FONT> <FONT STYLE="font-size: 10pt">shares of common stock </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Total shares of common stock outstanding(1)</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">8,702,237 shares. </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Number of shares of common stock issuable upon the exercise of warrants held by the selling security holders:</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 1,616,594 shares</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Use of Proceeds</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We will not receive any of the proceeds from the sale of our shares by the selling security holders. Any proceeds received by us from the exercise of warrants by the selling security holders will be used for general corporate purposes.</FONT><FONT STYLE="font-size: 10pt"> See &ldquo;Use of Proceeds&rdquo; on page 9.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Risk Factors</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; beginning on page 9 and the other information included in this prospectus for a discussion of factors you should carefully consider before investing in our securities.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>OTC Bulletin Board trading symbol</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">CSBR</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The number of shares of our common stock
        outstanding is based on the number of shares of our common stock outstanding as of August 31, 2015. This number does not include,
        as of August 31, 2015:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: left; text-indent: -10.65pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: justify; text-indent: -10.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;2,109,846
        shares of our common stock issuable upon exercise of outstanding warrants, with a weighted average exercise price of $5.82 per
        share;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: justify; text-indent: -10.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;2,014,507
        shares of our common stock issuable upon exercise of outstanding options, with a weighted average exercise price of $5.72 per share;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: justify; text-indent: -10.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;33,333
        shares of our common stock issuable upon the vesting of restricted stock units; and</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: justify; text-indent: -10.65pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;27,985,493
        shares of our common stock available for future grants under our 2010 Equity Incentive Plan.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.65pt; text-align: justify; text-indent: -10.65pt">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Any investment in
our common stock involves a high degree of risk. Investors should carefully consider all of the information contained in or incorporated
by reference in this prospectus, including the risks and uncertainties discussed in our Annual Report on Form 10-K for the year
ended April 30, 2015, incorporated by reference herein, and as updated in our subsequent periodic reports filed with the Securities
and Exchange Commission, before deciding whether to purchase our common stock. Our business, financial condition or results of
operations could be materially adversely affected by these risks if any of them actually occur. This prospectus also contains forward-looking
statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking
statements as a result of certain factors, including the risks we face as described below and elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive
any proceeds from the sale of shares of our common stock by the selling security holders. A portion of the shares covered by this
prospectus are issuable upon exercise of warrants to purchase our common stock. Upon any exercise of the warrants for cash, the
selling security holders would pay us the exercise price of the warrants. Under certain conditions set forth in the warrants, the
warrants are exercisable on a cashless basis. If the warrants are exercised on a cashless basis, we would not receive any cash
payment from the selling security holders upon any exercise of the warrants. Instead, the selling security holders would satisfy
their obligation to pay the exercise price through a formula-based transfer of warrant shares to us. The additional proceeds we
could receive from the exercise of such warrants have not yet been earmarked for any specific use beyond working capital needs
because there is no certainty that we will ever receive any proceeds from the exercise of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling security
holders will pay any underwriting discounts and commissions and expenses incurred by the selling security holders for brokerage,
accounting, tax or legal services or any other expenses incurred by the selling security holders in disposing of the shares. We
will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including,
without limitation, all registration and filing fees and fees and expenses of our counsel and our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>PRICE RANGE OF COMMON STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
sets forth the high and low quotation price for our common stock for each quarter within the last two fiscal years.&nbsp;&nbsp;Our
common stock, CSBR, is currently traded on the Nasdaq Capital market.&nbsp;The quotations represent prices between dealers and
do not reflect the retailer markups, markdowns or commissions, and may not represent actual transactions.&nbsp;Prior to being listed
on the Nasdaq Capital Market, our common stock traded over-the-counter and was quoted on the electronic Bulletin Board maintained
by the National Association of Securities Dealers. Our securities were classified as &ldquo;penny stocks&rdquo; as defined by existing
securities laws.&nbsp;&nbsp;This classification placed significant restrictions upon broker-dealers desiring to make a market in
such securities.&nbsp;&nbsp;The price range per share reflected in the table below is the high and low sales prices of our common
stock for the periods presented. Through the first quarter of Fiscal Year 2016, the historical trading prices represented are before
the reverse stock split on August 11, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Fiscal Year 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Second Quarter (through October 13, 2015)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9.00</TD><TD STYLE="width: 1%; text-align: left">*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.28</TD><TD STYLE="width: 1%; text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Fiscal Year 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Fiscal Year 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Fiscal Year 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>* </B>Closing price reflects a 1-for-12
reverse stock split of the Company&rsquo;s common stock effected on August 11, 2015 and the listing of the Company&rsquo;s common
stock on the Nasdaq Capital Market on August 21, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing price of
our common stock on the Nasdaq Capital Market on October 13, 2015 was $5.35 per share. As of October 13, 2015, there were approximately
2,100 record holders of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SELLING SECURITY HOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we refer to &ldquo;selling
security holders&rdquo; in this prospectus, we mean those persons listed in the table below, and the pledgees, donees, permitted
transferees, assignees, successors, and others who later come to hold any of the selling security holders&rsquo; interests in shares
of our common stock other than through a public sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates
to the offering and sale, from time to time, of up to 4,555,846 shares of our common stock, which amount includes 1,616,594 shares
of common stock issuable upon the exercise of warrants held by the selling security holders. The selling security holders may exercise
their warrants at any time in their sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 11, 2015,
the Company entered into a securities purchase agreement and a registration rights agreement (the &ldquo;2015 Amended and Restated
Registration Rights Agreement&rdquo;) with certain accredited investors in connection with our private placement sale of 2,939,252
units, each unit consisting of one share of the Company's common stock, par value $0.001 per share, and a warrant to buy 0.55 shares
of common stock at $5.76 per share, at a purchase price of $4.80 per unit, for an aggregate of approximately $14,000,000 (net proceeds
of approximately $13 million, which included the conversion of $2 million in convertible notes issued in December 2014). This transaction
closed on March 13, 2015. Pursuant to the terms of the registration rights agreement, we agreed to register a secondary offering
on such selling security holders&rsquo; behalf, all of the securities sold under the 2015 Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are registering the
following shares of common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; text-align: left"><FONT STYLE="font-size: 10pt">up to 2,939,252 shares of common stock issued to the selling security holders in the registrant&rsquo;s private placement offering closed on March 13, 2015; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">up to 1,616,594 shares of our common stock issuable upon the exercise of warrants issued to the selling security holders in the private placement offering closed on March 13, 2015. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling security
holders may sell some, all or none of their shares. We do not know how long the selling security holders will hold the shares offered
hereunder before selling them. We currently have no agreements, arrangements or understandings with the selling security holders
regarding the sale of any of the shares by them other than the 2015 Amended and Restated Registration Rights Agreement. The shares
offered by this prospectus may be offered from time to time by the selling security holders. The selling security holders may have
sold or transferred, in transactions exempt from the registration requirements of the Securities Act, some or all of their shares
since the date on which the information in the table is presented. Information about the selling security holders may change over
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth below is based on information known to us. The following table sets forth the name of each selling security holder, the number
of shares owned by such selling security holder (including shares underlying warrants) as of July 31, 2015, the number of shares
that may be offered under this prospectus by such selling security holder, and the number of shares of our common stock and the
percentage (if one percent or more) of our common stock to be owned by such selling security holder after completion of this offering,
assuming that all shares offered hereunder are sold as contemplated herein. The number of shares in the column &ldquo;Shares of
Common Stock That May Be Offered in the Offering&rdquo; represents all of the shares that a selling security holder may offer under
this prospectus, which includes the shares issuable upon exercise of the warrants covered by this prospectus. Except as otherwise
disclosed in this prospectus, none of the selling security holders has, or within the past three years has had, any position, office
or other material relationship with us. The selling security holders have advised us that they may enter into short sales in the
ordinary course of their business of investing and trading securities. Other than the costs of preparing and providing this prospectus
and a registration fee to the SEC, we are not paying any costs relating to the sales by the selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ownership reflected
in this table for each selling security holder is based upon information provided to us by the selling security holder and reflects
holdings as of July 31, 2015. The percentages of common stock owned after the offering are based on 8,702,237&nbsp;shares of our
common stock outstanding as of August 31, 2015, including the shares of common stock issued in the private placements. Beneficial
ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act. In computing the number
of shares owned by and the percentage ownership of a selling security holder, shares of common stock that could be issued upon
the exercise of outstanding options, warrants or other rights held by that selling security holder that are currently exercisable
or exercisable within 60 days of July 31, 2015 are considered outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Unless otherwise noted,
each person or group identified possesses sole voting and investment power with respect to the shares, subject to community property
laws where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; font-size: 8pt">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Outstanding<BR STYLE="font-size: 8pt"> Shares of<BR STYLE="font-size: 8pt"> Common&nbsp;Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Shares of<BR STYLE="font-size: 8pt"> Common&nbsp;Stock<BR STYLE="font-size: 8pt"> Subject to<BR STYLE="font-size: 8pt"> Options/Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Total Shares of<BR STYLE="font-size: 8pt"> Common Stock<BR STYLE="font-size: 8pt"> Beneficially&nbsp;Owned(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Shares of<BR STYLE="font-size: 8pt"> Common <BR STYLE="font-size: 8pt"> Stock<BR STYLE="font-size: 8pt"> That May <BR STYLE="font-size: 8pt"> Be <BR STYLE="font-size: 8pt"> Offered&nbsp;in<BR STYLE="font-size: 8pt"> the <BR STYLE="font-size: 8pt"> Offering (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Common Stock<BR STYLE="font-size: 8pt"> Beneficially&nbsp;Owned<BR STYLE="font-size: 8pt"> After Offering <BR STYLE="font-size: 8pt"> (1)(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">Percent<BR STYLE="font-size: 8pt"> After&nbsp;Offering</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="width: 22%; text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Joel Ackerman (3)</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">303,583</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">650,109</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">953,693</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">350,110</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">603,583</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 8pt">6.5</TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Battery Investment Partners IX, LLC (4)</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">19,340</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">5,313</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">24,653</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">7,992</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">16,660</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Battery Ventures IX, L.P. (5)</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">1,934,209</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">531,150</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,465,359</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">799,300</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">1,666,059</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">18.6</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Daniel Mendelson (6)</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">70,833</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">58,265</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">129,098</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">96,875</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">32,223</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Rich Molinsky</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">5,208</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,865</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">8,073</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">8,073</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Ronnie Morris (7)</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">311,916</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">645,665</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">957,581</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">350,110</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">607,471</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">6.5</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Sam Morse</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">15,625</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">8,594</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">24,219</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">24,219</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">New Enterprise Associates 14, L.P. (8)</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">1,562,500</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">859,375</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,421,875</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,421,875</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt">Perceptive Life Sciences Master Fund, Ltd.</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">178,645</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">98,256</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">276,901</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">276,901</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Sabby Healthcare Master Fund, Ltd.</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">112,500</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">61,875</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">174,375</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">174,375</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 8pt">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Titan Perc, Ltd.</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">29,687</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">16,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">46,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">46,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">*</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12pt; padding-left: 12pt; font-size: 8pt">Total</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">4,544,046</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,937,796</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">7,481,843</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">4,555,846</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">2,925,966</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 8pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 8pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">* Indicates less than one percent of the outstanding
shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Includes shares of common stock issuable upon the exercise of warrants, and is adjusted to reflect
the sale of shares pursuant to this offering.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Includes shares of common stock issuable upon the exercise of outstanding options, warrants or
other rights held by that selling security holder that are currently exercisable or exercisable within 60 days of July 31, 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Mr. Ackerman is the Company&rsquo;s Chief Executive Officer and a director.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Is under the same common control as Battery Ventures IX, L.P. (&ldquo;BVIX&rdquo;), as Battery
Partners IX, LLC (&ldquo;BPIX&rdquo;) is the sole manager of Battery Investment Partners IX, LLC (&ldquo;BIPIX&rdquo;), and the
sole general partner of Battery Ventures IX, L.P. Mr. Scott Tobin, one of our directors, is a member manager of BPIX. Mr. Tobin
expressly disclaims beneficial ownership over all Shares held by BVIX and BIPIX, except to the extent of his indirect pecuniary
interest therein. The Company has agreed that it will not approve or effect certain mergers or consolidations, and certain other
material decisions, without the consent of BVIX,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">Is under the same common control as BIPIX, as BPIX is the sole manager of BIPIX, and the sole general
partner of BVIX. Mr. Scott Tobin, one of our directors, is a member manager of BPIX. Mr. Tobin expressly disclaims beneficial ownership
over all Shares held by BVIX and BIPIX, except to the extent of his indirect pecuniary interest therein. The Company has agreed
that it will not approve or effect certain mergers or consolidations, and certain other material decisions, without the consent
of BVIX.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">Is one of our directors.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: justify">Dr. Morris is the Company&rsquo;s President and a director.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(8)</TD><TD STYLE="text-align: justify">For information regarding New Enterprise Associates 14, L.P., see &ldquo;Voting/Dispositive Power
for Selling Security Holders&rdquo; below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Voting/Dispositive Power for Selling
Security Holders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Set forth below is the natural person or persons
who exercise the sole or shared voting and/or dispositive powers with respect to the shares to be offered by the Selling Security
Holders that are legal entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 26%; text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Selling</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Security</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Holder</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Entity</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Natural Person(s) Who Exercise Sole</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>or Shared Voting Powers</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Natural Person(s) Who Exercise Sole</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>or Shared Dispositive Powers</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Battery Investment Partners IX, LLC (1)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Scott Tobin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Scott Tobin</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Battery Ventures IX, L.P. (2)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Scott Tobin</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Scott Tobin</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">New Enterprise Associates 14, L.P. (3)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD NOWRAP>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M. James Barrett, Peter J. Barris,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forest Baskett, Anthony Florence, Jr., Patrick
        J. Kerins,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Krishna Koliuri, David M. Mott,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Scott D. Sandell, Peter Sonsini,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ravi Viswanathan, Harry Weller</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">M. James Barrett, Peter J. Barris,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Forest Baskett, Anthony Florence, Jr., Patrick
        J. Kerins,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Krishna Koliuri, David M. Mott,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Scott D. Sandell, Peter Sonsini,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ravi Viswanathan, Harry Weller</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Perceptive Life Sciences Master Fund, Ltd. </FONT>(4)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Joseph Edelman</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Joseph Edelman</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Sabby Healthcare Master Fund, Ltd. (5)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hal Mintz</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hal Mintz</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">Titan Perc, Ltd. (6) </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Joseph Edelman</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Joseph Edelman</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Battery Investment Partners IX, LLC is under the same common control as Battery Ventures IX, L.P.
(&ldquo;BVIX&rdquo;), as Battery Partners IX, LLC (&ldquo;BPIX&rdquo;) is the sole manager of Battery Investment Partners IX, LLC
(&ldquo;BIPIX&rdquo;), and the sole general partner of Battery Ventures IX, L.P. Mr. Scott Tobin, one of our directors, is a member
manager of BPIX. Mr. Tobin expressly disclaims beneficial ownership over all shares held by BVIX and BIPIX, except to the extent
of his indirect pecuniary interest therein. The business address of BIPIX is 930 Winter Street, Suite 2500, Waltham, MA 02451.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Battery Ventures IX, L.P. is under the same common control as BIPIX, as BPIX is the sole manager of
BIPIX, and the sole general partner of BVIX. Mr. Scott Tobin, one of our directors, is a member manager of BPIX. Mr. Tobin expressly
disclaims beneficial ownership over all shares held by BVIX and BIPIX, except to the extent of his indirect pecuniary interest
therein. The business address of Battery Ventures IX, L.P. is 930 Winter Street, Suite 2500, Waltham, MA 02451.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">(3)</TD><TD STYLE="text-align: justify">The sole general partner of New Enterprise Associates 14, L.P. (&ldquo;NEA 14&rdquo;) is NEA Partners
14, L.P. (&quot;NEA Partners 14&quot;). NEA 14 GP, LTD (&quot;NEA 14 LTD&quot;) is the sole general partner of NEA Partners 14.
The individual directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony Florence, Jr., Patrick J.
Kerins, Krishna &quot;Kittu&quot; Koliuri, David M. Mott, Scott D. Sandell, Peter Sonsini, Ravi Viswanathan and Harry Weller. Each
of NEA Partners 14, NEA 14 LTD and M. James Barrett, Peter J. Barris, Forest Baskett, Anthony Florence, Jr., Patrick J. Kerins,
Krishna &quot;Kittu&quot; Koliuri, David M. Mott, Scott D. Sandell, Peter Sonsini, Ravi Viswanathan and Harry Weller expressly
disclaims beneficial ownership over all shares held by NEA 14, except to the extent of their indirect pecuniary interest therein.
The Company has agreed that it will not approve or effect certain mergers or consolidations, and certain other material decisions,
without the consent of NEA 14. The business address of NEA 14 is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093-4135.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">(4)</TD><TD STYLE="text-align: justify">Perceptive Advisors, LLC, serves as the investment manager of Perceptive Life Sciences Master Fund,
Ltd. Joseph Edelman is the manager of Perceptive Advisors, LLC. Each of Perceptive Advisors, LLC and Mr. Edelman expressly disclaims
beneficial ownership over all shares held by Perceptive Life Sciences Master Fund, Ltd., except to the extent of his indirect pecuniary
interest therein. The business address of Perceptive Advisors, LLC is 499 Park Avenue, 25<SUP>th</SUP> floor, New York, NSY 10022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify">Sabby Management, LLC serves as the investment manager of Sabby Healthcare Master Fund, Ltd. Hal Mintz
is the manager of Sabby Management, LLC. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the shares
held by Sabby Healthcare Master Fund, Ltd., except to the extent of its pecuniary interest therein. The business address of Sabby
Management, LLC is 10 Mountain Road, Suite 205, Upper Saddle River, NJ 07458.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">(6)</TD><TD STYLE="text-align: justify">Perceptive Advisors, LLC, serves as the investment manager of Titan Perc, Ltd. Joseph Edelman is the
manager of Perceptive Advisors, LLC. Each of Perceptive Advisors, LLC and Mr. Edelman expressly disclaims beneficial ownership
over all shares held by Titan Perc, Ltd., except to the extent of his indirect pecuniary interest therein. The business address
of Perceptive Advisors, LLC is 750 Washington Boulevard, 10<SUP>th</SUP> Floor, Stamford, CT 06901.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>DESCRIPTION OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 31, 2015,
our authorized capital stock consisted of 200,000,000 shares of common stock, $0.001 par value per share. As of August 31, 2015,
there are 8,702,237 shares of our common stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 11, 2015,
the Registrant filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware that effected a 1-for-12 reverse stock split of the Company&rsquo;s common stock. All share amounts
and stock prices relating to our common stock have been given effect for the 1-for-12 reverse split of our shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common
stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting. Holders of our
common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally
available funds. However, the current policy of our board of directors is to retain earnings, if any, for the operation and expansion
of the company. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all
of our assets which are legally available for distribution, after payment of or provision for all liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 31, 2015
we had 2,014,507 stock options issued and outstanding, of which 1,556,788 are exercisable, with a weighted average exercise price
of $5.72 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 31, 2015
we had 2,109,846 warrants outstanding, all of which are exercisable, with a weighted average exercise price of $5.82 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Delaware Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to Section
203 of the Delaware General Corporation Law. This provision generally prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years following the date the stockholder became an interested
stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">prior to such date, the board of directors approved either the business combination or the transaction
that resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors and also
officers and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares
held subject to the plan will be tendered in a tender or exchange offer; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">on or subsequent to such date, the business combination is approved by the board of directors and
authorized at an annual meeting or special meeting of stockholders and not by written consent, by the affirmative vote of at least
66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 203 defines
a business combination to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving
the interested stockholder;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation
of any stock of the corporation to the interested stockholder;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges
or other financial benefits provided by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section
203 defines an &ldquo;interested stockholder&rdquo; as any entity or person beneficially owning 15% or more of the outstanding
voting stock of a corporation, or an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding
voting stock of a corporation at any time within three years prior to the time of determination of interested stockholder status;
and any entity or person affiliated with or controlling or controlled by such entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statutory provisions
could delay or frustrate the removal of incumbent directors or a change in control of our company. They could also discourage,
impede, or prevent a merger, tender offer, or proxy contest, even if such event would be favorable to the interests of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amended and Restated Certificate
of Incorporation and Bylaw Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals
or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable.
In particular, the certificate of incorporation and bylaws, as applicable, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide our board of directors with the ability to alter its bylaws without stockholder approval;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provide that vacancies on our board of directors may be filled by a majority of directors in office,
although less than a quorum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such provisions may
have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These
provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and
in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change
in control of our company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and
to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential
ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company outweigh
the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an
improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, these provisions
could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored
takeover attempts. These provisions also may have the effect of preventing changes in our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our common stock is Mountain Share Transfer, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of our common
stock are currently quoted on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which
the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may
use any one or more of the following methods when selling shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell the shares as agent but may position
and resell a portion of the block as principal to facilitate the transaction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">short sales;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">broker-dealers may agree with the selling stockholders to sell a specified number of such shares
at a stipulated price per share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">a combination of any such methods of sale; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged
by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser)
in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary
in the types of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal
might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar
selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may
agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities
are imposed on that person under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common
stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b) or other applicable
provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee
or other successors in interest as selling stockholders under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from
time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b) or other applicable provision
of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or
other successors in interest as selling stockholders under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
and any broker-dealers or agent that are involved in selling the shares of common stock may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agent and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions
or discounts under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to
pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholders
against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders
have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers
regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with
a proposed sale of shares of common stock by any selling stockholder. If we are notified by any selling stockholder that any material
arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement
to this prospectus. If the selling stockholders use this prospectus for any sale of the shares of common stock, they will be subject
to the prospectus delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The anti-manipulation rules of Regulation M under the Securities
Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities that may
be offered by this prospectus has been passed upon for us by Epstein, Becker &amp; Green, P.C., New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ernst &amp; Young,
LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report
on Form 10-K for the year ended April 30, 2014, as set forth in their report, which is incorporated by reference in this prospectus
and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp;
Young, LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EisnerAmper, LLP, independent
registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K
for the year ended April 30, 2015, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere
in the registration statement. Our financial statements are incorporated by reference in reliance on EisnerAmper, LLP&rsquo;s report,
given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Securities and
Exchange Commission, or the SEC, allows us to &ldquo;incorporate by reference&rdquo; the information that we have filed with it,
meaning we can disclose important information to you by referring you to those documents already on file with the SEC. The information
incorporated by reference is considered to be part of this prospectus except for any information that is superseded by other information
that is included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This filing incorporates
by reference the following documents, which we have previously filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>&bull;</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Annual Report on Form
10-K for the fiscal year ended April 30, 2015, as filed with the SEC on July 29, 2015;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><B>&bull;</B></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our Quarterly Report on Form 10-Q for the three months ended July 31, 2015, as filed with the SEC on September 11, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><B>&bull;</B></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our Current Report on Form 8-K, as filed with the SEC on July 23, 2015, August 13, 2015, August 21, 2015 and August 31, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><B>&bull;</B></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our Definitive Proxy Statement filed with the SEC on August 28, 2015 and amended on September 1, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information contained in this prospectus, as updated and supplemented by any prospectus supplement, or that information
to which this prospectus or any prospectus supplement has referred you by reference. We have not authorized anyone to provide you
with any additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">These documents may
also be accessed through our website at www.championsoncology.com or as described under &ldquo;Prospectus Summary&mdash;Available
Information&rdquo; in this prospectus. The information and other content contained on or linked from our website are not part of
this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein modifies or supersedes
such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide, without
charge, to each person, including any beneficial owner, to whom this prospectus is delivered, on the written or oral request of
such person, a copy of any or all of the reports or documents incorporated by reference in this prospectus but not delivered with
this prospectus. Any request may be made by writing or calling us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">David Miller<BR>
Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">One University Plaza, Suite 307</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hackensack, New Jersey 07601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(201) 808-8400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DMiller@championsoncology.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2,939,252 shares of Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1,616,594 shares of Common Stock issuable
upon the exercise of Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October
14, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in
this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus,
regardless of the time of the delivery of this prospectus or any sale of these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X
M#D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$"
M 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,#_\  $0@ ;@$Q P$1  (1 0,1 ?_$ ,4   $"!P$
M           )"@$" P4&!P@$ 0 ! P4! 0               @<( 00%!@D#
M"A   00! P,"! 0#! 8'"0   0(#! 4& !$'(1((,0E!41,487$B%9$R%H&A
ML2/10E)B,Q?PP9(D)A@9X7*"0U-CI"5%$0 ! @0% 04& @@#!0<%   ! @,
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M:T6_\5['W*P:>X4+$RJ>H309X]4D'KVPXVU^8>2]HU::O;]RJ ZE)$E2<&G
MG!84.@QE/WPM3XR^^5DM=)@8WY18C&N*Q2VHZN1\!AHB6,5.X!DW&+*66);8
M W<7$4DCJ0@]!J+W(7I46T7*_9JRE(!5Y2E%0,L=*29D3RS,3<XJ]=U4P&;7
MR*R7E*6E!>"4HT@D J(0$C#.'#?%?,/'?->(U^<\89?3YEB]FV5,6=1*9?#+
MP *XDUC],B!,9WV6R\AMU!]4ZAW?]OWG;E>JWWAI=,\G/4)>T3P([Q'1G:6\
MMO[VM";UMVH;J*=0F E0)'<>LXVDDDI23ZD G\]M8H2E@9CM[8VA)) )$B1E
MV1'1%8-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00
M:((-$$&B"#1!!H@@T00:((-$$&B"#1!%!;P02"-]OSZ_I*MO3;?Y:0I>@*4Y
M@@2D>W]#A"2H)6E*OSF0_P >R$>/<G]S.G\983_$O$SU;?\ /%G"49KKBFY=
M7QO!FM@L6-JE*PA^]D-'OBPU?(+<';LE4@^&.%*O?CZ+Y?&U-69M0*/EGYI)
MQD3*20 )GKTPQB'/J5]2E)QK3G:NVUMN[E<0OS2%R\@2&@B0.I1).&&F7;DT
MKS+,LGSS(K?,<UO;3*,JOY;MA<7MU,=FV,V5(4"XMQUPJ^FVD )0VCM;;2 E
M( &ND=JL=LVY1-6NU,MLTR4@22 ,AW1QWONZ;[NNYNW:]U#E15J43J4293/8
M9QB^R%=5(W^ Z[;?W:S#P0\@)(Q'?&(^YJ)?*H >$2!!_E/0#KOZG_';02VT
MSYCQ(\!.$H0'3)H_-WX?MBLE (.RALGY^ORZ^NVDM>94-AYDM^4H3&I4C[1(
MR@6@MJT*2HK&<A,>^*:V]R-E)]/G_P"S27GD4R)/XO'((^82[SA(^R$C23DO
M3U^7_&*H8^D.]1"P>G:%;'<_'H#Z;:&PI]KS'$R1./8/>3\](IU+N4RB0EU$
MYF)=^H[01UZ==]O\->[04%!+?UDX>/3QCS4\M9F_)2>O0D=<>D=)^,_E5R_X
MIYU$S3BR\=8CK>:_JG#YS[[F*9A #B2]$MZU*BVU("-PS,:"9#"MCWE.Z2V7
M('&>WN2+>[27%I*+BCZ7$I&H'MZ>Z<NV'?XIYEW7Q/?6JRVU#B[2?J8*B$$=
MG7\)F'G_ (@>7W'/F!Q=%S_!/K0+"N4S5YIBD]8-KB=\&$N+KY92GL>9?2?J
M1WD]'62#T.X',;?VPKQQ_?%VFYI 8FKRU_O(!DDRZ82F)X1VRX@Y9L7+>W$7
M>UG36!"?-1F$K*0525(3$YR,HZT0KN&Y '4CH=_]&M%2M"YE&(!E#KIUR^<2
M,3:5%8-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00
M:((-$$&B"#1!!H@@T00:((-$$2]P_P"@U28UZ/S0G4-.O\L)X>XSYF0/$#AF
M5:4ZXTSE3.?NJ+C:HDD+;9G)C;3\FFQ@0I=5C[3J5K!V#CRVT#U.SL<1\;5/
M).Y44*D?]*I2EQY4Y?+/(=I[AC*(Z^I#F-CA[9CM6RK5>J]);92,2V92UX9?
MMAE%D>37&6W]OE&26<V[R'(+*5<75Q9/+DS;"TFNJ?DRWWE[J6XXI6V^X"0
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M.NLX5M&;F54V)817.[LF0I,>;&>[5;+2S*C*<:<[% @@*.Q&QU[5#-11KTO
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M;72LTUTIV'%E00$K4I GI41F#[L9QFMD;IY!X YB9V%>*VIK+:_5-M:5.%2
ME1EJ .1D<#"L?O?%UOP\J'&7WVE'ES$4=Z'7&E$*AW))[FU)5VJW^?II@O2K
M1-G?XHZQ*7DBD=/S"<R,1GV$81+KUN5M52\1_P!4HG5MG[IH229?*J4QAT/6
M-L^T&I;G@AQ4M;BW7?W3-PIQQQ3CA RJQVW6X2HA.YVZ]-:QSS34]'RC<:=A
M"6Z,>7I0!)()0"9#O)G&Z>D9];W"=!5U!*ZLK<*E'$D#($]PP$)?^XYYG\U<
M]>0#GAMXUV5K7U<3)8N!W0QJ:Y7W6?9FZM";"MD6\=UN178K1E2DO]JT(<4T
MM;A*$@:?CAKB_9.T]K#DK??E//N,J<2RZF:4)3]!D<RH"?ME$3/4+S1O3D/D
MMOA_CXNL4R7-"W65$*<)!U E/1!PEW1Y8_L0\KR,2_?9G..*-\B+B?>G'SCM
MH]4(L%)^H8KF1F:J:M?U^AD!@D$;@$==+5ZJ;+3UIM[5J9&WBO3.21\O\/AT
M)CS9]#6ZGMJF\N79T;M\W5]:YR[-7;\(QKP7\O.=_#KR0C>)GDA96\_#)^51
M\&?K\EL7;63Q_?V+J&:*ZQNYE*<=DXI:ONM!3?>MKZ;H<;[2E23=\J<<;)Y#
MV6OD/8_ET]P;9#GEM)TA8."Y@=4IF<>HBWX4Y9WUQ+RFKBCD)3U3:W%A"5O*
M)+1P*2F> "B #VSA:7W15]G@?Y!.-N*;/],P AQ"U(4"K(*KKWI(4.X ;['^
M[48.&:5JJY2M-'5I2[1EPA:%":5$ RF.N(B:_J<K:ICA:YUUM=6S6^6DH6@R
M4D*E.1&4QA#;OVU_.2U\3^6$565VTV7PIR--AUN:5STN1*;QFT#B8T',ZU#R
ME_3^Q#OT9J$$!V.-]NYI.IO<Y\.V_>-D=NUG;:;O%,DJT)$BH 3*3+''\8YH
M^FKU!7WCK=+&W;Z\\_MZJ<2C4M1(3,R!$^S],X5Z]\2UB6_BEQ;<4EBU)KK;
ME6DG0;*MF%46PA2<8MY$:5'?8<V>8>:6%)()!2=]1L],E$ACD&KM]TITJ:11
M$%"TX!0< .!ZQ+[UO7D#BJW7W;U2335%:"HMJP6DHP!ET!Z1V3[696OP-\?5
MO+==6K'[@*4M:G%*(RBZ&Y6LE2B/Q.F^YY32V[E"X4U$TA%*7VTI0D22G4A.
M0]L/1Z7*U^MX4L]:ZI2G5MN+))F2$J4-/AAE#>;D>USCW"_/#)N,>0N7FN.,
M09RG,L>Q&)?2'/Z?QVJQ29*A1JJNHG)L"!)R.[7$*RXXKO>6O;J $ZF%:;;:
MN&>+V-Q6VW,7&]OH05.! *PE8FH:L2$S )P,HYY[@N=QYSYNNNVMQ7:HM=D9
MJ2VVGS"E (,@ )@ D3CKVJ]GGRBX3Y9X[R+@7R";1C#N3UIR#+::3,Q+(\6I
MT/!V;/73?=3*;)V'&$%H-#<+4M(4CLWTV%S]0NS-T;8K;;N.T--W93#B&R4)
M4"LI(1(X$'41TPZ0\UJ](O(6Q-V6Z[[(O;C]F-4RMQ272E2&PL%2N\A()GC#
ME2N9DQ(L:+)F29S\>*PP[,>[ [+<:92ER4Z&TMMI>>4GN4$I"03TZ; 0Y>>#
MM3_*0$-3G(98]/ 1T@I&W::A9HJA:G*K2 7#BHGM)[3'M^L/_N_Q&O71X1>?
M9K_\0PBY[Y$!Y[Q+QF>@@M5O,>-+D;_#[NKNX[9_[9U(KTMO-T_)0;/YF%9^
M*8A#Z\*5Q[B'STST(N34^SZ1#1]2MU=P_ ]?G_HUTN=0E#J@G$:C''9\ /*
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MS'[/([)U:DI3]O60GY/TP5="X\M 0@?%2@-<W;#0/7:ZT]FIQJJ'7$IRG*9
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MNHI++)G\YXXS")6J978P(:)ZU2J67]NXGM^E]LZUW!0!&X+X4]AX;YZM3O\
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M[2WHITC'M)[?T[HVRM8(*=E?J!&XVZ;C;?U^&LLI2DY)44]HE^V,SJ0I)!4
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MX7N&U=O[G5?-V.!"&4$M@8DK/61Z 89]8?;U2;9W_O/CUG;6RZ9SSW7AYI)
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MPAP=\H%0[AMVD'J-;95[EM[%F-]U?]'2F:C^\#D0>Z-TN.Z;11[>_N0+6:
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M^8G%E;S5XAVUSDSBH>7X)@T?E?&\CAMAB;1Y?CE$BZ>7%4G9<=B<&ELNMI(
M2K<?J2G9P-ST+EWVH*BM6TY<6&@ZDHE(* $SAV_JC?-W6QN];.%4_C<J=D.!
M7^8 $R[HPKVO>/X$'@R+S7:6$O(.2N=ID_*\UR>W5]:WFIC39<&!7KD']1BQ
M1'4YL D*<<4K;TUBN*Z FTJW-6XU]>HIF<]*#E/V1C.(;618E[FK,;A7*(F<
M]*#@)^R%.=.M#M0:((-$$&B"#1!!H@@T00:((-$$>";%CRF9+$EAJ0S)9<9>
M8>;0ZT\TMI3;C3C:PI"VW$**5 @@@[>FD+==84BH8)#C:@009$8Y@]T>%13L
M5C*J&H2DLO)*53 (4#A)0.8ET,-1_<V]LNVX<M+KGS@FD?L^);63*M<PPZL8
M<DS..I\E:G9MI"CH2ZY(P^0\KO4D)[H1)'_#V[9[<%<V45UID;7W2X475(0F
MG<),ES)!UDG$@2P]HZQR>]4OI?K-MW%6]-K-%=E>4M3[;8 #<I$%*4@2GCC+
MNA$%]*DI"MP0M"5H4VH$!*MNTDI VWZC4PU.MT3K=+4+\RK=!T*1D  29R[I
MQS^5Y3JE_;(4VTCZ@O.<Y=1VQX]S\S_$Z]CCB<X2DE'TDCPBOW%(]2!^!/K\
M/3\-)"4I,T@ ]T45\YU+Q5VG$Q#?IOOT^!_#_H=+*E$S)),4&&6$4U+.X*5$
M;#H02-NN_35.DND4TCL$3N*5MON=]_7<[]=]]4  ,P)&%#!.D?3V=(&W"G;9
M92K?H02"#OT.X^6A141@3JZ8P)2V5 .#Y)X^'6+O3T=UD5K74%%6SKR\O9;-
M;4TU7'7.GV<V4L-LQ(D9@+5(>>4OHD G;J>F^L+=KA8[%1*J[BXEJ8FI1($^
M\GK[3&7M%IN&X;BFWVAIUY8,D@3)'@.GLAZO[9W _-_ 'CQ58GS=E\BWLYKR
M+3'<.D.MS?\ EK2RF.]O&&[7J_)*EK+JVB5-1EDH;)&^N6G->Y]G[JWPNOVN
MT&V6R4+4F24NK&"EE(D,3U.).)[^X?IIV1OC9O'C-%NQY;BW6D+;2XI2EM(4
MD$(FHDB0D-(P$H4:;]#UW_4=M-.D. GS.W#PZ1)!"DJ2-&0PBII4*@T00:((
MHNLH<04%IM:5?I4E:4E)200=P4D$;'TV.^DJ0A:/+6 6ST(F/=E"5)2I*DJ
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2$&B"#1!!H@@T00:((-$$?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
